Biocon obtains approval for weight management drug, Liraglutide, in the United States

Biocon Limited, an innovation-led global biopharmaceuticals company, announced it has received approval from the U.S. FDA for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda®). The drug-device combination formulation is used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity. The approval reinforces Biocon's commitment to expanding access to critical therapies for patients globally, with the U.S. being an important market in this strategy. The total addressable market opportunity for GLP-1 in weight loss in the U.S. was US $127 million as of December 2025.